
Opinion|Videos|September 17, 2024
Management of Skin and Nail AEs: Advice to Patients and Caregivers
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts provide advice to patients and caregivers on managing oral and skin toxicities.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What advice do you provide to patients and/or caregivers to manage their oral and skin toxicities?
Advertisement
Related to this article

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast Cancer
2
FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data
3
FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer
4
FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLC
5

